TEGSEDI Pregnancy Surveillance Program

NCT04270058 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-08-19

No results posted yet for this study

Summary

This is a worldwide safety surveillance study of pregnancy outcomes in women with hATTR-PN who may have been exposed or were not exposed to TEGSEDI prior to or during the pregnancy and of pediatric outcomes up to 1 year of age.

Conditions

  • Hereditary Transthyretin-mediated Amyloidosis With Polyneropathy
  • Pregnancy

Interventions

DRUG

inotersen

TEGSEDI injection, for subcutaneous use

Sponsors & Collaborators

  • Akcea Therapeutics

    lead INDUSTRY

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2030-11-15
Completion
2030-11-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270058 on ClinicalTrials.gov